International Stem Cell CORP

International Stem Cell Corp. is a clinical-stage biotechnology company that develops human parthenogenetic stem cell-based therapies and also operates two commercial businesses: Lifeline Cell Technology for human cell research products and Lifeline Skin Care for cosmetic products. The company combines early-stage regenerative medicine development with revenue-generating biomedical and consumer product lines.

−0,5 %

55,7 %

−4,6 %

+0,2 %

0.74

0.41

— International Stem Cell CORP
%
Biomedical research products55% Human primary cells, media, and related research tools sold through LCT.
Cosmetic products25% Lifeline Skin Care branded cosmetic products sold online and through ecommerce partners.
Therapeutic development0% Preclinical and clinical-stage stem cell programs targeting neurological diseases.
Stem cell platform and cell lines20% UniStemCell™ hpSC lines and related proprietary cell differentiation know-how.

The company sells to biomedical researchers, laboratories, and commercial partners that need human cell culture...

  • Biomedical research laboratoriesprimary

    Buy primary human cells and media for cell culture, assay development, and translational research.

  • Ecommerce skincare consumersprimary

    Buy branded cosmetic products directly online for personal care use.

  • OEM and distributor partnerssecondary

    Purchase or distribute LCT products to extend market reach in Europe and Asia.

  • Therapeutic collaboratorsemerging

    Potential partners for licensing, clinical development, manufacturing, and commercialization of hpSC programs.

The company is headquartered in the United States and sells its cosmetic products domestically through its own website,...

  • •United States is the main market for skincare ecommerce sales
  • •Europe and Asia are key channels for LCT research products
  • •Domestic online channels include branded website and Amazon
  • •International distributors extend reach without heavy direct sales cost
  • •U.S. regulatory and funding environment shapes therapeutic development

Management is focused on funding and advancing stem cell therapeutic programs while using the commercial businesses to...

01
Develop hpSC therapeutic candidateslong-term

Clinical programs are the long-term value driver but require substantial time and capital.

02
Secure external funding and partnershipsshort-term

The company states it needs additional capital to sustain operations and advance development.

03
Expand commercial revenue streamsmedium-term

Biomedical and skincare sales help offset R&D burn and support liquidity.

04
Improve manufacturing and gross marginmedium-term

Better production efficiency can raise gross profit in the existing commercial businesses.

The company faces substantial financing risk because its therapeutic programs are pre-revenue and management says...

critical

Liquidity shortfall

Management says it needs significant additional capital to sustain operations and fund R&D.

Scope
Corporate operations and clinical development
Materiality
high
high

Clinical development failure

hpSC therapeutic candidates are early-stage and may not prove safe or effective.

Scope
Parkinson's disease, TBI, and stroke programs
Materiality
high
high

Regulatory and compliance burden

Cell-based therapies and cosmetics require ongoing regulatory oversight and quality control.

Scope
FDA/GMP compliance and cosmetic product regulation
Materiality
high
medium

Channel concentration and partner dependence

Commercial products rely on a limited set of ecommerce, OEM, and distributor channels.

Scope
LCT and LSC sales channels
Materiality
medium
medium

IP and patent expense

Protecting stem cell technologies requires ongoing filing, prosecution, and defense costs.

Scope
Proprietary cell lines and differentiation methods
Materiality
medium
Revenue mix and gross margin
Quarterly gross margin volatility
R&D expense recognition
Reported operating loss and comparability
Lease and facility allocations
Operating expense trend
Related-party debt
Net loss and liquidity
Going-concern assumptions
Disclosure risk and valuation context

Stemtech Corp

STEK · Wholesale-Drugs, Proprietaries & Druggists' Sundries

CRYO CELL INTERNATIONAL INC

CCEL · Services-Misc Health & Allied Services, NEC

Century Therapeutics, Inc.

IPSC · Biological Products, (No Diagnostic Substances)

Yubo International Biotech Ltd

YBGJ · Electromedical & Electrotherapeutic Apparatus

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

CELZ · Biological Products, (No Diagnostic Substances)

IMMUNIC, INC.

IMUX · Pharmaceutical Preparations

: 28.4.2026